The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Identifieur interne : 001116 ( PubMed/Corpus ); précédent : 001115; suivant : 001117The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Auteurs : Christian Manegold ; Anne-Marie C. Dingemans ; Jhanelle E. Gray ; Kazuhiko Nakagawa ; Marianne Nicolson ; Solange Peters ; Martin Reck ; Yi-Long Wu ; Odd Terje Brustugun ; Lucio Crin ; Enriqueta Felip ; Dean Fennell ; Pilar Garrido ; Rudolf M. Huber ; Aurélien Marabelle ; Marcin Moniuszko ; Françoise Mornex ; Silvia Novello ; Mauro Papotti ; Maurice Pérol ; Egbert F. Smit ; Kostas Syrigos ; Jan P. Van Meerbeeck ; Nico Van Zandwijk ; James Chih-Hsin Yang ; Caicun Zhou ; Everett VokesSource :
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [ 1556-1380 ] ; 2017.
Abstract
Over the past few years, there have been considerable advances in the treatments available to patients with metastatic or locally advanced NSCLC, particularly those who have progressed during first-line treatment. Some of the treatment options available to patients are discussed here, with a focus on checkpoint inhibitor immunotherapies (nivolumab and pembrolizumab) and antiangiogenic agents (bevacizumab, ramucirumab, and nintedanib). It is hypothesized that combining immunotherapy with antiangiogenic treatment may have a synergistic effect and enhance the efficacy of both treatments. In this review, we explore the theory and potential of this novel treatment option for patients with advanced NSCLC. We discuss the growing body of evidence that proangiogenic factors can modulate the immune response (both by reducing T-cell infiltration into the tumor microenvironment and through systemic effects on immune-regulatory cell function), and we examine the preclinical evidence for combining these treatments. Potential challenges are also considered, and we review the preliminary evidence of clinical efficacy and safety with this novel combination in a variety of solid tumor types.
DOI: 10.1016/j.jtho.2016.10.003
PubMed: 27729297
Links to Exploration step
pubmed:27729297Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.</title><author><name sortKey="Manegold, Christian" sort="Manegold, Christian" uniqKey="Manegold C" first="Christian" last="Manegold">Christian Manegold</name><affiliation><nlm:affiliation>Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. Electronic address: prof.manegold@t-online.de.</nlm:affiliation></affiliation></author><author><name sortKey="Dingemans, Anne Marie C" sort="Dingemans, Anne Marie C" uniqKey="Dingemans A" first="Anne-Marie C" last="Dingemans">Anne-Marie C. Dingemans</name><affiliation><nlm:affiliation>Department of Pulmonary Diseases, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Gray, Jhanelle E" sort="Gray, Jhanelle E" uniqKey="Gray J" first="Jhanelle E" last="Gray">Jhanelle E. Gray</name><affiliation><nlm:affiliation>Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation></affiliation></author><author><name sortKey="Nakagawa, Kazuhiko" sort="Nakagawa, Kazuhiko" uniqKey="Nakagawa K" first="Kazuhiko" last="Nakagawa">Kazuhiko Nakagawa</name><affiliation><nlm:affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Nicolson, Marianne" sort="Nicolson, Marianne" uniqKey="Nicolson M" first="Marianne" last="Nicolson">Marianne Nicolson</name><affiliation><nlm:affiliation>Oncology Department, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Peters, Solange" sort="Peters, Solange" uniqKey="Peters S" first="Solange" last="Peters">Solange Peters</name><affiliation><nlm:affiliation>Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Reck, Martin" sort="Reck, Martin" uniqKey="Reck M" first="Martin" last="Reck">Martin Reck</name><affiliation><nlm:affiliation>Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Yi Long" sort="Wu, Yi Long" uniqKey="Wu Y" first="Yi-Long" last="Wu">Yi-Long Wu</name><affiliation><nlm:affiliation>Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.</nlm:affiliation></affiliation></author><author><name sortKey="Brustugun, Odd Terje" sort="Brustugun, Odd Terje" uniqKey="Brustugun O" first="Odd Terje" last="Brustugun">Odd Terje Brustugun</name><affiliation><nlm:affiliation>Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Crin, Lucio" sort="Crin, Lucio" uniqKey="Crin L" first="Lucio" last="Crin">Lucio Crin</name><affiliation><nlm:affiliation>Medical Oncology Department, Perugia University Medical School, Perugia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Felip, Enriqueta" sort="Felip, Enriqueta" uniqKey="Felip E" first="Enriqueta" last="Felip">Enriqueta Felip</name><affiliation><nlm:affiliation>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Fennell, Dean" sort="Fennell, Dean" uniqKey="Fennell D" first="Dean" last="Fennell">Dean Fennell</name><affiliation><nlm:affiliation>Department of Oncology, University of Leicester and Leicester University Hospitals, Leicester, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Garrido, Pilar" sort="Garrido, Pilar" uniqKey="Garrido P" first="Pilar" last="Garrido">Pilar Garrido</name><affiliation><nlm:affiliation>Servicio de Oncología Médica, IRYCIS Hospital Universitario Ramón y Cajal, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Huber, Rudolf M" sort="Huber, Rudolf M" uniqKey="Huber R" first="Rudolf M" last="Huber">Rudolf M. Huber</name><affiliation><nlm:affiliation>Ludwig-Maximilians-Universität München, University Hospital, Division of Respiratory Medicine and Thoracic Oncology, Münich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Marabelle, Aurelien" sort="Marabelle, Aurelien" uniqKey="Marabelle A" first="Aurélien" last="Marabelle">Aurélien Marabelle</name><affiliation><nlm:affiliation>Gustave Roussy, Université Paris-Saclay, Département d'Innovation Thérapeutique et d'Essais Précoces, INSERM U1015, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moniuszko, Marcin" sort="Moniuszko, Marcin" uniqKey="Moniuszko M" first="Marcin" last="Moniuszko">Marcin Moniuszko</name><affiliation><nlm:affiliation>Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Mornex, Francoise" sort="Mornex, Francoise" uniqKey="Mornex F" first="Françoise" last="Mornex">Françoise Mornex</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Université Claude Bernard, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Novello, Silvia" sort="Novello, Silvia" uniqKey="Novello S" first="Silvia" last="Novello">Silvia Novello</name><affiliation><nlm:affiliation>Department of Oncology, University of Turin, Turin, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Papotti, Mauro" sort="Papotti, Mauro" uniqKey="Papotti M" first="Mauro" last="Papotti">Mauro Papotti</name><affiliation><nlm:affiliation>Department of Oncology, University of Turin, Turin, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Perol, Maurice" sort="Perol, Maurice" uniqKey="Perol M" first="Maurice" last="Pérol">Maurice Pérol</name><affiliation><nlm:affiliation>Département de Cancérologie, Médicale Centre Léon Bérard, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Smit, Egbert F" sort="Smit, Egbert F" uniqKey="Smit E" first="Egbert F" last="Smit">Egbert F. Smit</name><affiliation><nlm:affiliation>Department of Pulmonary Diseases and Department of Thoracic Oncology, VU University Medical Centre, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Syrigos, Kostas" sort="Syrigos, Kostas" uniqKey="Syrigos K" first="Kostas" last="Syrigos">Kostas Syrigos</name><affiliation><nlm:affiliation>Oncology Unit GPP, Sotiria General Hospital, Athens University School of Medicine, Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Van Meerbeeck, Jan P" sort="Van Meerbeeck, Jan P" uniqKey="Van Meerbeeck J" first="Jan P" last="Van Meerbeeck">Jan P. Van Meerbeeck</name><affiliation><nlm:affiliation>Thoracic Oncology, Antwerp University Hospital and Ghent University, Edegem, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Van Zandwijk, Nico" sort="Van Zandwijk, Nico" uniqKey="Van Zandwijk N" first="Nico" last="Van Zandwijk">Nico Van Zandwijk</name><affiliation><nlm:affiliation>Asbestos Diseases Research Institute, University of Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Chih Hsin Yang, James" sort="Chih Hsin Yang, James" uniqKey="Chih Hsin Yang J" first="James" last="Chih-Hsin Yang">James Chih-Hsin Yang</name><affiliation><nlm:affiliation>Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Caicun" sort="Zhou, Caicun" uniqKey="Zhou C" first="Caicun" last="Zhou">Caicun Zhou</name><affiliation><nlm:affiliation>Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China.</nlm:affiliation></affiliation></author><author><name sortKey="Vokes, Everett" sort="Vokes, Everett" uniqKey="Vokes E" first="Everett" last="Vokes">Everett Vokes</name><affiliation><nlm:affiliation>Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27729297</idno><idno type="pmid">27729297</idno><idno type="doi">10.1016/j.jtho.2016.10.003</idno><idno type="wicri:Area/PubMed/Corpus">001116</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001116</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.</title><author><name sortKey="Manegold, Christian" sort="Manegold, Christian" uniqKey="Manegold C" first="Christian" last="Manegold">Christian Manegold</name><affiliation><nlm:affiliation>Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. Electronic address: prof.manegold@t-online.de.</nlm:affiliation></affiliation></author><author><name sortKey="Dingemans, Anne Marie C" sort="Dingemans, Anne Marie C" uniqKey="Dingemans A" first="Anne-Marie C" last="Dingemans">Anne-Marie C. Dingemans</name><affiliation><nlm:affiliation>Department of Pulmonary Diseases, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Gray, Jhanelle E" sort="Gray, Jhanelle E" uniqKey="Gray J" first="Jhanelle E" last="Gray">Jhanelle E. Gray</name><affiliation><nlm:affiliation>Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</nlm:affiliation></affiliation></author><author><name sortKey="Nakagawa, Kazuhiko" sort="Nakagawa, Kazuhiko" uniqKey="Nakagawa K" first="Kazuhiko" last="Nakagawa">Kazuhiko Nakagawa</name><affiliation><nlm:affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Nicolson, Marianne" sort="Nicolson, Marianne" uniqKey="Nicolson M" first="Marianne" last="Nicolson">Marianne Nicolson</name><affiliation><nlm:affiliation>Oncology Department, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Peters, Solange" sort="Peters, Solange" uniqKey="Peters S" first="Solange" last="Peters">Solange Peters</name><affiliation><nlm:affiliation>Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Reck, Martin" sort="Reck, Martin" uniqKey="Reck M" first="Martin" last="Reck">Martin Reck</name><affiliation><nlm:affiliation>Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Wu, Yi Long" sort="Wu, Yi Long" uniqKey="Wu Y" first="Yi-Long" last="Wu">Yi-Long Wu</name><affiliation><nlm:affiliation>Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.</nlm:affiliation></affiliation></author><author><name sortKey="Brustugun, Odd Terje" sort="Brustugun, Odd Terje" uniqKey="Brustugun O" first="Odd Terje" last="Brustugun">Odd Terje Brustugun</name><affiliation><nlm:affiliation>Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.</nlm:affiliation></affiliation></author><author><name sortKey="Crin, Lucio" sort="Crin, Lucio" uniqKey="Crin L" first="Lucio" last="Crin">Lucio Crin</name><affiliation><nlm:affiliation>Medical Oncology Department, Perugia University Medical School, Perugia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Felip, Enriqueta" sort="Felip, Enriqueta" uniqKey="Felip E" first="Enriqueta" last="Felip">Enriqueta Felip</name><affiliation><nlm:affiliation>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Fennell, Dean" sort="Fennell, Dean" uniqKey="Fennell D" first="Dean" last="Fennell">Dean Fennell</name><affiliation><nlm:affiliation>Department of Oncology, University of Leicester and Leicester University Hospitals, Leicester, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Garrido, Pilar" sort="Garrido, Pilar" uniqKey="Garrido P" first="Pilar" last="Garrido">Pilar Garrido</name><affiliation><nlm:affiliation>Servicio de Oncología Médica, IRYCIS Hospital Universitario Ramón y Cajal, Madrid, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Huber, Rudolf M" sort="Huber, Rudolf M" uniqKey="Huber R" first="Rudolf M" last="Huber">Rudolf M. Huber</name><affiliation><nlm:affiliation>Ludwig-Maximilians-Universität München, University Hospital, Division of Respiratory Medicine and Thoracic Oncology, Münich, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Marabelle, Aurelien" sort="Marabelle, Aurelien" uniqKey="Marabelle A" first="Aurélien" last="Marabelle">Aurélien Marabelle</name><affiliation><nlm:affiliation>Gustave Roussy, Université Paris-Saclay, Département d'Innovation Thérapeutique et d'Essais Précoces, INSERM U1015, Villejuif, France.</nlm:affiliation></affiliation></author><author><name sortKey="Moniuszko, Marcin" sort="Moniuszko, Marcin" uniqKey="Moniuszko M" first="Marcin" last="Moniuszko">Marcin Moniuszko</name><affiliation><nlm:affiliation>Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Mornex, Francoise" sort="Mornex, Francoise" uniqKey="Mornex F" first="Françoise" last="Mornex">Françoise Mornex</name><affiliation><nlm:affiliation>Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Université Claude Bernard, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Novello, Silvia" sort="Novello, Silvia" uniqKey="Novello S" first="Silvia" last="Novello">Silvia Novello</name><affiliation><nlm:affiliation>Department of Oncology, University of Turin, Turin, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Papotti, Mauro" sort="Papotti, Mauro" uniqKey="Papotti M" first="Mauro" last="Papotti">Mauro Papotti</name><affiliation><nlm:affiliation>Department of Oncology, University of Turin, Turin, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Perol, Maurice" sort="Perol, Maurice" uniqKey="Perol M" first="Maurice" last="Pérol">Maurice Pérol</name><affiliation><nlm:affiliation>Département de Cancérologie, Médicale Centre Léon Bérard, Lyon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Smit, Egbert F" sort="Smit, Egbert F" uniqKey="Smit E" first="Egbert F" last="Smit">Egbert F. Smit</name><affiliation><nlm:affiliation>Department of Pulmonary Diseases and Department of Thoracic Oncology, VU University Medical Centre, Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Syrigos, Kostas" sort="Syrigos, Kostas" uniqKey="Syrigos K" first="Kostas" last="Syrigos">Kostas Syrigos</name><affiliation><nlm:affiliation>Oncology Unit GPP, Sotiria General Hospital, Athens University School of Medicine, Athens, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Van Meerbeeck, Jan P" sort="Van Meerbeeck, Jan P" uniqKey="Van Meerbeeck J" first="Jan P" last="Van Meerbeeck">Jan P. Van Meerbeeck</name><affiliation><nlm:affiliation>Thoracic Oncology, Antwerp University Hospital and Ghent University, Edegem, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Van Zandwijk, Nico" sort="Van Zandwijk, Nico" uniqKey="Van Zandwijk N" first="Nico" last="Van Zandwijk">Nico Van Zandwijk</name><affiliation><nlm:affiliation>Asbestos Diseases Research Institute, University of Sydney, New South Wales, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Chih Hsin Yang, James" sort="Chih Hsin Yang, James" uniqKey="Chih Hsin Yang J" first="James" last="Chih-Hsin Yang">James Chih-Hsin Yang</name><affiliation><nlm:affiliation>Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Caicun" sort="Zhou, Caicun" uniqKey="Zhou C" first="Caicun" last="Zhou">Caicun Zhou</name><affiliation><nlm:affiliation>Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China.</nlm:affiliation></affiliation></author><author><name sortKey="Vokes, Everett" sort="Vokes, Everett" uniqKey="Vokes E" first="Everett" last="Vokes">Everett Vokes</name><affiliation><nlm:affiliation>Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</title><idno type="eISSN">1556-1380</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Over the past few years, there have been considerable advances in the treatments available to patients with metastatic or locally advanced NSCLC, particularly those who have progressed during first-line treatment. Some of the treatment options available to patients are discussed here, with a focus on checkpoint inhibitor immunotherapies (nivolumab and pembrolizumab) and antiangiogenic agents (bevacizumab, ramucirumab, and nintedanib). It is hypothesized that combining immunotherapy with antiangiogenic treatment may have a synergistic effect and enhance the efficacy of both treatments. In this review, we explore the theory and potential of this novel treatment option for patients with advanced NSCLC. We discuss the growing body of evidence that proangiogenic factors can modulate the immune response (both by reducing T-cell infiltration into the tumor microenvironment and through systemic effects on immune-regulatory cell function), and we examine the preclinical evidence for combining these treatments. Potential challenges are also considered, and we review the preliminary evidence of clinical efficacy and safety with this novel combination in a variety of solid tumor types.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27729297</PMID><DateCreated><Year>2016</Year><Month>10</Month><Day>12</Day></DateCreated><DateRevised><Year>2017</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-1380</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2017</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</Title><ISOAbbreviation>J Thorac Oncol</ISOAbbreviation></Journal><ArticleTitle>The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.</ArticleTitle><Pagination><MedlinePgn>194-207</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1556-0864(16)31142-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtho.2016.10.003</ELocationID><Abstract><AbstractText>Over the past few years, there have been considerable advances in the treatments available to patients with metastatic or locally advanced NSCLC, particularly those who have progressed during first-line treatment. Some of the treatment options available to patients are discussed here, with a focus on checkpoint inhibitor immunotherapies (nivolumab and pembrolizumab) and antiangiogenic agents (bevacizumab, ramucirumab, and nintedanib). It is hypothesized that combining immunotherapy with antiangiogenic treatment may have a synergistic effect and enhance the efficacy of both treatments. In this review, we explore the theory and potential of this novel treatment option for patients with advanced NSCLC. We discuss the growing body of evidence that proangiogenic factors can modulate the immune response (both by reducing T-cell infiltration into the tumor microenvironment and through systemic effects on immune-regulatory cell function), and we examine the preclinical evidence for combining these treatments. Potential challenges are also considered, and we review the preliminary evidence of clinical efficacy and safety with this novel combination in a variety of solid tumor types.</AbstractText><CopyrightInformation>Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Manegold</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany. Electronic address: prof.manegold@t-online.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dingemans</LastName><ForeName>Anne-Marie C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Diseases, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Jhanelle E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakagawa</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nicolson</LastName><ForeName>Marianne</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oncology Department, Aberdeen Royal Infirmary, Aberdeen, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Solange</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reck</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Airway Research Center North, Grosshansdorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yi-Long</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brustugun</LastName><ForeName>Odd Terje</ForeName><Initials>OT</Initials><AffiliationInfo><Affiliation>Department of Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crinò</LastName><ForeName>Lucio</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Oncology Department, Perugia University Medical School, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Felip</LastName><ForeName>Enriqueta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fennell</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Oncology, University of Leicester and Leicester University Hospitals, Leicester, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garrido</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Oncología Médica, IRYCIS Hospital Universitario Ramón y Cajal, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Rudolf M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Ludwig-Maximilians-Universität München, University Hospital, Division of Respiratory Medicine and Thoracic Oncology, Münich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marabelle</LastName><ForeName>Aurélien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gustave Roussy, Université Paris-Saclay, Département d'Innovation Thérapeutique et d'Essais Précoces, INSERM U1015, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moniuszko</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mornex</LastName><ForeName>Françoise</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Université Claude Bernard, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novello</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Oncology, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papotti</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Oncology, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérol</LastName><ForeName>Maurice</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Département de Cancérologie, Médicale Centre Léon Bérard, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smit</LastName><ForeName>Egbert F</ForeName><Initials>EF</Initials><AffiliationInfo><Affiliation>Department of Pulmonary Diseases and Department of Thoracic Oncology, VU University Medical Centre, Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syrigos</LastName><ForeName>Kostas</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Oncology Unit GPP, Sotiria General Hospital, Athens University School of Medicine, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Meerbeeck</LastName><ForeName>Jan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Thoracic Oncology, Antwerp University Hospital and Ghent University, Edegem, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Zandwijk</LastName><ForeName>Nico</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Asbestos Diseases Research Institute, University of Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chih-Hsin Yang</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Caicun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncology, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vokes</LastName><ForeName>Everett</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Chicago Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Thorac Oncol</MedlineTA><NlmUniqueID>101274235</NlmUniqueID><ISSNLinking>1556-0864</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiangiogenesis</Keyword><Keyword MajorTopicYN="N">Combination therapy</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">NSCLC</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>09</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27729297</ArticleId><ArticleId IdType="pii">S1556-0864(16)31142-X</ArticleId><ArticleId IdType="doi">10.1016/j.jtho.2016.10.003</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001116 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001116 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27729297
|texte= The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27729297" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |